Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

K D Hove; Cecilie Brøns; Kai Erik Vinther Færch; S S Lund; J S Petersen; A E Karlsen; Pia Rossing; J F Rehfeld; A Vaag

doi:10.1007/s00125-012-2714-y

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

K D Hove, Cecilie Brøns, Kai Erik Vinther Færch, S S Lund, J S Petersen, A E Karlsen, Pia Rossing, J F Rehfeld, A Vaag

Department of Clinical Medicine

Research output: Contribution to journal › Journal article › Research › peer-review

34 Citations (Scopus)

Abstract

Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

Original language	English
Journal	Diabetologia
Volume	56
Issue number	1
Pages (from-to)	22-30
Number of pages	9
ISSN	0012-186X
DOIs	https://doi.org/10.1007/s00125-012-2714-y
Publication status	Published - 2013

Access to Document

10.1007/s00125-012-2714-y

Cite this

Hove, K. D., Brøns, C., Færch, K. E. V., Lund, S. S., Petersen, J. S., Karlsen, A. E., Rossing, P., Rehfeld, J. F., & Vaag, A. (2013). Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia, 56(1), 22-30. https://doi.org/10.1007/s00125-012-2714-y

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes : a randomised double-blind prospective placebo-controlled study. / Hove, K D; Brøns, Cecilie; Færch, Kai Erik Vinther; Lund, S S; Petersen, J S; Karlsen, A E; Rossing, Pia; Rehfeld, J F; Vaag, A.

In: Diabetologia, Vol. 56, No. 1, 2013, p. 22-30.

Research output: Contribution to journal › Journal article › Research › peer-review

Hove, KD, Brøns, C, Færch, KEV, Lund, SS, Petersen, JS, Karlsen, AE, Rossing, P, Rehfeld, JF & Vaag, A 2013, 'Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study', Diabetologia, vol. 56, no. 1, pp. 22-30. https://doi.org/10.1007/s00125-012-2714-y

Hove KD, Brøns C, Færch KEV, Lund SS, Petersen JS, Karlsen AE et al. Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia. 2013;56(1):22-30. https://doi.org/10.1007/s00125-012-2714-y

Hove, K D ; Brøns, Cecilie ; Færch, Kai Erik Vinther ; Lund, S S ; Petersen, J S ; Karlsen, A E ; Rossing, Pia ; Rehfeld, J F ; Vaag, A. / Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes : a randomised double-blind prospective placebo-controlled study. In: Diabetologia. 2013 ; Vol. 56, No. 1. pp. 22-30.

@article{23072be35ac64f3092a7a5388c9a097c,

title = "Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study",

abstract = "Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.",

author = "Hove, {K D} and Cecilie Br{\o}ns and F{\ae}rch, {Kai Erik Vinther} and Lund, {S S} and Petersen, {J S} and Karlsen, {A E} and Pia Rossing and Rehfeld, {J F} and A Vaag",

year = "2013",

doi = "10.1007/s00125-012-2714-y",

language = "English",

volume = "56",

pages = "22--30",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes

T2 - a randomised double-blind prospective placebo-controlled study

AU - Hove, K D

AU - Brøns, Cecilie

AU - Færch, Kai Erik Vinther

AU - Lund, S S

AU - Petersen, J S

AU - Karlsen, A E

AU - Rossing, Pia

AU - Rehfeld, J F

AU - Vaag, A

PY - 2013

Y1 - 2013

N2 - Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

AB - Recent studies suggest that proton pump inhibitor treatment may increase insulin secretion and improve glucose metabolism in type 2 diabetes. In a randomised double-blind prospective placebo-controlled 2 × 2 factorial study, we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.

U2 - 10.1007/s00125-012-2714-y

DO - 10.1007/s00125-012-2714-y

M3 - Journal article

C2 - 23011351

VL - 56

SP - 22

EP - 30

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 1

ER -